ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

China flag China · Delayed Price · Currency is CNY
12.79
-0.34 (-2.59%)
May 21, 2026, 3:04 PM CST
Market Cap3.27B +53.7%
Revenue (ttm)849.26M +1.6%
Net Income20.36M -75.5%
EPS0.08 -75.8%
Shares Out256.06M
PE Ratio153.52
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,952,400
Average Volume16,716,756
Open14.35
Previous Close13.13
Day's Range12.77 - 14.35
52-Week Range9.16 - 15.20
Beta0.54
RSI46.15
Earnings DateApr 28, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule... [Read more]

Sector Healthcare
Founded 2005
Employees 1,196
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300254
Full Company Profile

Financial Performance

In 2024, SHE:300254's revenue was 846.61 million, an increase of 5.92% compared to the previous year's 799.31 million. Earnings were 42.19 million, an increase of 67.45%.

Financial Statements